This phase II trial tests the effect of botensilimab and balstilimab before surgery (neoadjuvant) in treating patients with high-risk clear cell renal cell can…

Clear Cell Renal Cell CarcinomaStage II Renal Cell Cancer AJCC v8Stage III Renal Cell Cancer AJCC v8+1 more

~Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07516366

Phase 2

A Phase II Study of Neoadjuvant Ivonescimab in Patients With High-Risk, Localized RCC

This phase II trial studies how well ivonescimab works prior to surgery in treating patients with high-risk clear cell kidney (renal cell) cancer that has not …

Localized Clear Cell Renal Cell CarcinomaResectable Clear Cell Renal Cell CarcinomaStage II Renal Cell Cancer AJCC v8+2 more

~Estimated

~$10 – $6,250

City of Hope Medical CenterNCT07226544

Phase 2

Impact of Microbiome Modulation With CBM588 in Combination With Pembrolizumab for Adjuvant Therapy of High-Risk, Resected Renal Cell Carcinoma (RCC)

This phase II trial compares the effect of adding a Live Biotherapeutic Product called CBM588 to pembrolizumab versus pembrolizumab alone in preventing return …

Clear Cell Renal Cell CarcinomaSarcomatoid Renal Cell CarcinomaStage II Renal Cell Cancer AJCC v8+2 more

~Estimated

~$10 – $6,250

City of Hope Medical CenterNCT07037004